Search
forLearn
5 / 801 resultslearn DECAPEPTIDE-28
learn retinoic acid
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Actsyl®
Research
5 / 1000+ results
research Dermatological adverse events with taxane chemotherapy
Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
The combination therapy is effective and well-tolerated for treating esophageal cancer.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
Community Join
5 / 1000+ resultscommunity The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Pyrilutamide/KX-826 for women?
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.